Acute Coronary Syndromes II Flashcards
Paradigm for treating STEMI
“Time is muscle” Goal is immediate restoration of blood flow to occluded vessel.
Therapy that all MI patients get
Anti-coagulation, anti-platelet, anti-ischemic, adjunctive
Anti-ischemic Rx
Beta-blockers (relieve ischemic pain by decreasing cardiac work and oxygen demand. Reduce infarct size and arrhythmias. Mortaility benefit.)
Nitrates (enhance blood flow by coronary vasodilation and decrease preload. But don’t give to STEMI patients early, or with RV infarct)
CCB (NonDHP’s reduce HR and contractility. No mortality benefit in ACS.)
Antithrombotic therapy
Antiplatelets and anticoagulants.
Antiplatelets decrease platelet aggregation and are effective in arterial circulation.
Anticoagulants limit blood from clotting.
Aspirin
Effective across entire spectrum of ACS. Should be given as soon as possible to all patients with suspected ACS. Has rapid anti-platelet effect and reduces coronary occlusion and recurrent ischemic events after fibrinolytic therapy.
Clopidogrel/Prasugrel
Thienopyridine derivative that is an IRREVERSIBLE inhibitor of the P2Y12 Receptor. Indicated in all patients with USA/NSTEMI unless surgery planned. Takes 5 days to recover.
Prasugrel has more even effect. Newer generation.
Lots of interindividual variability in response to clop.
Glycoprotein IIb/IIIa inhibitors
Super potent, inhibit the final common pathway of platelet aggregation, but use has declined with antiplatelet drugs.
Anticoagulation therapy
Heparin
Bivalirudin
Factor Xa inhibitor
Heparin
Standard anticoagulant
Bivalrudin
Direct thrombin inhibitor. Can be used instead of heparin
Factor Xa inhibitor
Similar efficacy to LMWH but less bleeding
How does heparin work?
Unfractionated heparin: Binds to antithrombin, causes conformational change that causes it to bind to thrombin more avidly, also factor Xa.
LMWH: Binds to antithrombin, binds to just factor Xa more avidly.
Conservative treatment of USA/NSTEMI patients
Medications alone with angio/revasc only if clinical worstening or evidence of ischemia
Invasive treatment of USA/NSTEMI patients
Urgent cardiac cath.
How to determine risk of USA/NSTEMI
TIMI risk score. Risk of adverse outcomes increases with each point